

Prior Authorization DRUG Guidelines

**Lidocaine Patch (Lidoderm)**

Effective Date 11/22/16

Developed 11/10/16 by R. Sterling, MD

Last Approval Date: 01/24/17, 1/23/18, 1/22/19, 2/18/20, 2/2/21,  
2/1/22, 1/31/23

**(Formulary Exclusion – For Exception Review Use Only)**

**Lidoderm** (lidocaine patch 5%) is comprised of an adhesive material containing 5% lidocaine, which is applied to a non-woven polyester felt backing and covered with a polyethylene terephthalate (PET) film release liner. Lidocaine is an amide-type local anesthetic agent that stabilizes neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. The penetration of lidocaine into intact skin after application of Lidoderm is sufficient to produce an analgesic effect, but less than the amount necessary to produce a complete sensory block.

**Pre-authorization Criteria:** approved only for pain associated with post-herpetic neuralgia

**Dosing:** up to three patches applied over the most painful areas; apply only once per 24-hour period

**Dosage Forms:** 10 cm × 14 cm patches; each adhesive patch contains 700 mg of lidocaine (50 mg per gram adhesive) in an aqueous base

**How Supplied:** Carton of 30 patches

**Adverse Reactions/Precautions Significant:** apply only to intact dry skin; keep out of the reach of small children and pets (chewing or ingestion would be toxic); watch for local skin reaction/sensitivity; wash hands after application; avoid eye contact

**Drug Interactions:** should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic.

## REFERENCES:

Davies PS and Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. *Drugs*. 2004;64(9):937-947.

Lidoderm (lidocaine patch 5%) [prescribing information]. Malvern, PA: Endo Pharmaceuticals; January 2015.

Sakai RI, Lattin JE. Lidocaine ingestion. *Am J Dis Child*. 1980;1344(3):323.

## Revision History:

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD  
 Date Approved by P&T Committee: 1/24/17  
 Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD  
 Date Approved by P&T Committee: 1/23/18  
 Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD  
 Date Approved by P&T Committee: 1/22/19  
 Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD  
 Date Approved by P&T Committee: 2/18/20  
 Date Reviewed/No Updates: 2/2/21 by H. Taekman, MD; R. Sterling, MD  
 Date Approved by P&T Committee: 2/2/21  
 Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD  
 Date Approved by P&T Committee: 2/1/22  
 Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD  
 Date Approved by P&T Committee: 1/31/23

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/2/21	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review